This Fortune Merchant Purchases 1 Million 440 Thousand Nissan Masks From 12 Production Lines, Which Will Be Directly Supplied To Zhuhai'S Most Cattle In The Next 5 Years.

The local sports and welfare lottery program provider, the national drug Polytron Technologies Inc (hereinafter referred to as the "national pharmaceutical technology stock"), announced in February 21st that the company entered into an order contract through the wholly-owned subsidiary, the National Pharmaceutical Technology Enterprise Management Limited (the national pharmaceutical technology enterprise management) and the right Star intelligent control system engineering (Shanghai) Limited by Share Ltd (Quan Xing Zhi control). Purchase contract, the national pharmaceutical technology enterprise management will order Quan Xing Zhi to order 2 medical disposable masks full automatic production line, and it is expected that the equipment will be delivered no later than March 12, 2020.


Reporters noted that in February 20th, the national pharmaceutical technology shares also signed an order contract with the Shenzhen branch of the national science and Technology Co., Ltd. (hereinafter referred to as the "National Science") and the Shanghai Fu Fu intelligent manufacturing (Tianjin) Co., Ltd. (hereinafter referred to as "Shang Fu Yi"), and the State Department will order ten medical disposable masks at RMB 4 million 600 thousand yuan. Automatic production line.


Guo Ke has invested 6 of its equipment in the form of production equipment to Shandong De Ji medical supplies Co., Ltd. (hereinafter referred to as "De Ji medical"). Under the premise of jointly operating the joint venture company, it has made full use of high-quality core production equipment to create revenue. The remaining 4 devices are planned to be used in Hongkong to establish its own production line.


At present, China national pharmaceutical technology shares are actively looking for clean workshops that are available for use. At the same time, we are also seeking to provide relevant training, technical support and other support to the Hongkong Productivity Council and Hongkong Science Park in Hongkong for the establishment of infrastructure and cleaning workshop.


The full automatic production line of medical disposable masks purchased by the State Department is a fully automatic high-end equipment with a production volume of 100 pieces per minute. The State Department put the equipment in the plant of the joint venture company to assist its layout in the high-end production line. The new equipment is put into use, so that the joint venture company can effectively achieve high production efficiency in the short term, increase production capacity, reduce costs, and facilitate manual operation to reduce losses and stabilize production. The introduction of high-end equipment in the joint venture has also made the quality of medical masks advanced.


According to the reporter's announcement, up to now, the national pharmaceutical technology stock has ordered 10 production line equipment, and now additional 2 production lines are being purchased. A total of 12 production lines will be put into use in the short term. 4 production lines are planned to be placed in Hongkong, China, for the establishment of a new production line, with a capacity of 480 thousand masks per day, and an annual capacity of about 175 million. The remaining 8 production lines are 960 thousand masks per day, with an annual capacity of about 350 million. These production lines can provide more than 500 million total masks per year for mainland China and Hongkong, China.


So, how can the masks and protective clothing be released by the regulatory authorities? Through which channel will we enter the hands of consumers?


Reporters found that in February 17, 2020, China pharmaceutical technology shares signed a strategic cooperation framework agreement with Zhuhai HUAFA Group Co., Ltd. (hereinafter completed as "Zhuhai HUAFA"), and reached a stable cooperative relationship between medical supplies procurement and supply. According to the agreement, the shares of Sinopharm technology will be based on the medical and business networks owned by the company, and the buyers and the market as the medical supplies of the company. The Zhuhai HUAFA, the recipient, will establish a long-term strategic cooperative relationship. When the epidemic of pneumonia is raging, Zhuhai HUAFA will assume the heavy responsibility for the supply of medical materials in Guangdong and even in the whole country. The cooperation agreement will establish a cooperative relationship and a direction of development for a period of five years. The scope and contents of the cooperation are as follows:


1, medical materials procurement cooperation


Zhuhai HUAFA relies on its good reputation of state-owned enterprises, capital advantages, and the professional advantages of its subordinate business and service sectors in supply chain integrated services such as commodity procurement, distribution, customs declaration, inspection and transportation, etc., and carries out all-round, multi-level and wide-ranging cooperation with China national pharmaceutical technology shares in the field of medical equipment and medical materials trade. Including, but not limited to:


Zhuhai HUAFA, as the purchaser and market docking provider of the medical materials of the national pharmaceutical technology stock company, is responsible for the docking, procurement, transportation and customer relationship maintenance of medical materials in the territory of the domestic enterprises, and realizes the management and operation of the medical materials from the stock market of Chinese medicine technology to the demand terminal market.


China pharmaceutical technology shares, as an important medical product supplier of Zhuhai HUAFA overseas, is responsible for relying on "Internet +" technology, using big data to analyze and screen market demand, and assisting in optimizing procurement processes.


The two sides have established close cooperation with high quality logistics and customs clearance enterprises to form a smooth cooperation between warehouses and warehouses, and logistics and customs clearance. All the goods and materials are supplied to Zhuhai HUAFA and its related agencies, as well as the relevant organs of national pharmaceutical technology share.


2. major health industry chain cooperation


Relying on investment layout in biomedicine, medical devices and other fields, Zhuhai HUAFA has extensive cooperation with China National Pharmaceutical Technology Stock in the field of big health in terms of equity investment, technological innovation, R & D and production, channel promotion and market sales, so as to promote bilateral business development.


China pharmaceutical technology shares, as an important partner of Zhuhai HUAFA, provide technical support and channel support for Zhuhai HUAFA's business development in the field of health including medical mask production. It helps Zhuhai HUAFA connect high-quality medical device manufacturers, giving priority to medical products and raw materials supply, equity investment, strategic mergers and acquisitions, industrial investment and professional consulting services. Wait for an opportunity.


Reporters learned from the announcement that Zhuhai HUAFA, founded in 1980, is one of two leading state-owned enterprises in Zhuhai. It has been ranked among the top 500 enterprises in China for four consecutive years in 2016, ranking 330 in 2019, and forty-third in the top 500 list of Guangdong enterprises. We successfully built "3A credit main cluster" such as HUAFA group, HUAFA shares and HUAFA comprehensive development, ranking the forefront of Guangdong Province in terms of credit level and the number of high-quality credit entities.


HUAFA group is holding four HUAFA shares, Huajin capital, Huajin International Capital and Zhuangchen holding company, as well as two new three board listed companies of Hua Guan technology and Hua Guan capacitor. The regional layout has expanded from Zhuhai to more than 60 major cities in Beijing, Shanghai, Guangzhou, Shenzhen and Wuhan, and Hongkong, Macao, San Francisco, Tel Aviv and so on. Zhuhai HUAFA is also one of the emergency medical supplies procurement centers in Guangdong, and is responsible for purchasing medical supplies in Guangdong.


Next, we obtained a stable stake in the national pharmaceutical technology shares. In February 18th, we passed the 51% equity interest in the transfer of Shandong De Ji medical supplies Co., Ltd. (hereinafter referred to as the "medical service") through a wholly owned subsidiary, Guo Ke and Cui Guodong and Li Wei (hereinafter referred to as "former shareholders") and Beijing Xin post Investment Consulting Co., Ltd. (hereinafter referred to as "letter mail"). A joint venture contract shall be signed. In accordance with the joint venture contract, the original shareholders will transfer the 51% share of the joint venture company to the State Council with the total price of RMB 1 through friendly negotiation. The company will invest in the joint venture company on the basis of the equity ratio and jointly operate the joint venture company, Shandong De Ji medical supplies Co., Ltd. (hereinafter referred to as "De Ji medical"). The medical company is mainly engaged in the production and sale of disposable respirators, medical respirators, medical protective clothing, surgical gowns, surgical caps and surgical shoes.


The original shareholders guarantee that the medical products production license and other related approvals used for the production of disposable respirators, medical masks and medical protective clothing before March 15, 2020. The minimum production of disposable respirators and medical respirators should be set at no less than 500000 per day. The minimum output of medical protective clothing shall be no less than 5000 per day. Pieces. Thereafter, the next step will be planned according to the actual situation.


The registered capital is 5000000 yuan. The company's shareholders have four sides, and the state holds 51% of the joint venture company's equity (2550000 yuan). Mr. Cui Guodong holds 24% of the joint venture company's investment (RMB 1200000). Mr. Li Wei holds a 12% stake in the joint venture company (RMB 600000), and Beijing post office holds 13% of the joint venture company's equity (RMB 650000), and the parties need to hold it on or before May 31, 2020. The proportion of shares is financed.


Reporters here read the announcement learned that the Chinese medicine technology shares formerly known as the public color shares, founded in 1999, in November 2002 on the Hongkong stock exchange gem, as China's leading provider of sports and welfare lottery program, public color technology is currently authorized in 21 provinces and municipalities in the country, for the sports lottery issuing agency and welfare lottery issuing agency through the comprehensive lottery. The distribution network provides lottery equipment, software, related services and integrated marketing solutions.


According to the financial report, the first quarter results for the 3 months ended September 30, 2019, the shares of Sinopharm technology shares reached HK $50 million 549 thousand, an increase of 8.29 times compared with the same period last year. The loss of shareholders accounted for 4 million 130 thousand Hong Kong dollars, narrowing 67.7% compared with the same period last year. The gross profit margin of the service is lower than that of the lottery related services and Internet + Solution Services recorded in 2018.